Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Colorectal cancer in 2017

Practice-changing updates in the adjuvant and metastatic setting

Nature Reviews Clinical Oncology volume 15, pages 77–78 (2018)Cite this article

Subjects

2017 has been full of new discoveries that will influence the treatment of colorectal cancer. In the adjuvant setting, 3 months of chemotherapy might now be considered a new standard of care. Various other new treatments and promising biomarkers have also become available that will improve survival outcomes and the quality of life of many patients with metastatic disease.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Shi, Q. et al. Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 versus 6 months) for patients (pts) with stage III colon cancer (CC): the IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration [abstract]. J. Clin. Oncol. 35 (Suppl.), LBA1 (2017).

    Article  Google Scholar 

  2. Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409–413 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Overman, M. J. et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 18, 1182–1191 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Arnold, D. et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann. Oncol. 28, 1713–1729 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Tejpar, S. et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the crystal and fire-3 trials. JAMA Oncol. 3, 194–201 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Aljehani, M. A. et al. Association of primary tumor site with mortality in patients receiving bevacizumab and cetuximab for metastatic colorectal cancer. JAMA Surg. http://dx.doi.org/10.1001/jamasurg.2017.3466 (2017).

  8. Guinney, J. et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21, 1350–1356 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Lenz, H.-J. et al. Impact of consensus molecular subtyping (CMS) on overall survival (OS) and progression free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance) [abstract]. J. Clin. Oncol. 35 (Suppl.), 3511 (2017).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Alberto Puccini and Heinz-Josef Lenz are at the Division of Medical Oncology, Suite 3456, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue, Los Angeles, California 90033, USA.,

    Alberto Puccini & Heinz-Josef Lenz

Authors
  1. Alberto Puccini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Heinz-Josef Lenz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Heinz-Josef Lenz.

Ethics declarations

Competing interests

A.P. declares no competing interests. H.-J.L. has received financial support for clinical trials from Merck Serono and Roche, and honoraria for advisory board membership and lectures from Bayer, Boehringer Ingelheim, Genentech, Merck Serono and Roche.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Puccini, A., Lenz, HJ. Practice-changing updates in the adjuvant and metastatic setting. Nat Rev Clin Oncol 15, 77–78 (2018). https://doi.org/10.1038/nrclinonc.2017.185

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2017.185

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing